The strong sequential growth in KOMZIFTI revenue and patient starts is the primary catalyst. Monitor upcoming quarterly reports for continued commercial ramp and any pipeline updates for ziftomenib in additional indications.
Drug in focus
KURA drug pipeline →KOMZIFTI
◆ Mixed Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in the U.S. since November 2025.
- Next catalyst
- None dated
What to watchKOMZIFTI is already approved and generating growing revenue, so the defining binary event has passed. Watch for ASH 2026 (December 2026) where ziftomenib combination data in newly diagnosed AML will be presented -- strong data could support a major label-expansion opportunity into the frontline setting, while weak data would cap the upside thesis. Also track quarterly sales growth trajectory as the key near-term value driver.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $10.09entry
- T+1 · 3mo ago +7.63%α +7.83% · $10.86
- T+5 · 3mo ago +16.06%α +18.02% · $11.71
- T+20 · 2mo ago +12.88%α +14.63% · $11.39
- T+60 · 11d ago −27.95%α −22.47% · $7.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology reported Q1 2026 earnings with an EPS of -$0.83, beating consensus of -$0.88 by 5.7%, and revenue of $20.2M in line with estimates. The highlight is KOMZIFTI (ziftomenib) net product revenue of $9.1M, up 57% sequentially, with 115 new patient starts, up 35% sequentially, indicating strong commercial traction for its lead drug. The EPS beat is modest and the company remains pre-profitable, but the accelerating product revenue growth is the key positive signal for the stock.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.83 beat consensus of -$0.88 by 5.7%
- Revenue of $20.2M in line with consensus estimates
- KOMZIFTI (ziftomenib) net product revenue of $9.1M, up 57% sequentially
- Approximately 115 new patient starts for KOMZIFTI, up 35% sequentially
Financial Impact
KOMZIFTI product revenue of $9.1M, up 57% sequentially, driving total revenue to $20.2M
Risk Factors
- Company remains pre-profitable with negative EPS
- Competition in the AML space could pressure KOMZIFTI adoption
- Reliance on a single product for revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344045 |
Track record
29 reports on KURA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers